Discovery of dengue virus inhibitors
Document Type
Article
Publication Date
1-1-2020
Abstract
To date, there is still no approved anti-dengue agent to treat dengue infection in the market. Although the only licensed dengue vaccine, Dengvaxia is available, its protective efficacy against serotypes 1 and 2 of dengue virus was reported to be lower than serotypes 3 and 4. Moreover, according to WHO, the risk of being hospitalized and having severe dengue increased in seronegative individuals after they received Dengvaxia vaccination. Nevertheless, various studies had been carried out in search of dengue virus inhibitors. These studies focused on the structural (C, prM, E) and non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) of dengue virus as well as host factors as drug targets. Hence, this article provides an overall up-to-date review of the discovery of dengue virus inhibitors that are only targeting the structural and non-structural viral proteins as drug targets.
Keywords
Drug discovery, Dengue virus, Virus inhibitors, Structural proteins, Non-structural proteins, Drug targets
Divisions
fac_med,Science
Funders
Universiti Malaya (UMRG-RP027A-15AFR),Universiti Malaya (PG046-2016A)
Publication Title
Current Medical Chemistry
Volume
27
Issue
30
Publisher
Bentham Science Publ Ltd
Publisher Location
EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES